Skip to main content
Article thumbnail
Location of Repository

Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007

By R Elema, C Mills, O Yun, K Lokuge, C Ssonko, N Nyirongo, V Mtonga, H Zulu, D Tu, M Verputten and D P O'Brien


A cross-sectional study of patients living with HIV/ AIDS treated during 2003 to 2007 in decentralized, rural health centers in Zambia was performed to measure virological outcomes after 12 months of antiretroviral therapy and identify factors associated with virological failure. Data from 228 patients who started antiretroviral therapy >12 months prior were analyzed. In all, 93% received stavudine + lamivudine + nevirapine regimens, and median antiretroviral therapy duration was 23.5 months (interquartile range 20-28). Of the 205 patients tested for viral load, 177 (86%) had viral load <1000 copies/mL. Probability of developing virological failure (viral load >1000 copies/mL) was 8.9% at 24 months and 19.6% at 32 months. Predictors for virological failure were <100% adherence, body mass index <18.5 kg/m(2), and women <40 years old. Of those with virological failure who underwent 3 to 6 months of intensive adherence counseling, 45% obtained virological success. In a remote, resource-limited setting in decentralized health centers, virological and immunological assessments of patients on antiretroviral therapy >12 months showed that positive health outcomes are achievable

Topics: antiretroviral therapy, HIV, rural health centers, sub-Saharan Africa, viral load
Year: 2009
DOI identifier: 10.1177/1545109709331472
OAI identifier:
Provided by: MSF Field Research

Suggested articles


  1. Efficacy of antiretroviral therapy programs in resource-poor settings: a metaanalysis of the published literature. Clin Infect Dis.
  2. (2007). Evaluation of antiretroviral therapy for HIVþ adults and children in the Arua HIV/AIDS care program,
  3. (2008). Fact Sheets on HIV and AIDS,
  4. First-line treatment choices proving challenging for African ART programmes.
  5. ICoNA Study Group. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study.
  6. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.
  7. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis. 2007;196(suppl 3):S464-S468.
  8. (2004). Increased access to ART in resource-poor settings in Me´decins Sans Frontie`res programmes: outcomes of adults at 18 months of treatment. Presented at:
  9. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis.
  10. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort.
  11. (2009). Reply to Vogenthaler. Clin Infect Dis. 2007;44:1387-1388 [letter].
  12. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi.
  13. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
  14. Second-line antiretroviral therapy in resource-limited settings: the experience of Me´decins Sans Frontie`res.
  15. Sensitivity and specificity of using CD4þ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand.
  16. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.